speb/financial-data huggingface dataset:
Financial ratios for IDN — quarterly report dated 2025-12-31
Total revenue: 6635000
Gross profit: 6065000
Operating income: 1494000
Net income: 1552000
Capital expenditures: 8000
Operating cash flow: 2394000
Depreciation & amortization: 190000
Net tangible assets: 10518000
Owner earnings: 1734000
Return on net tangible assets (%): 16.486023958927554
Capex to operating income (%): 0.535475234270415
Buffett classification: The Great
Stock price: 6.68
P/E ratio: 106.2672083896308
Shares outstanding: 20251221
Book value: 20697000
P/B ratio: 6.536123896216843
Market cap (USD): 135278156.28
Debt to equity: 0
Current ratio: 3.675211416490486
Quick ratio: 3.675211416490486
Effective tax rate (%): 3.602484472049689
COGS to revenue (%): 8.590806330067823
R&D to revenue (%): 19.18613413715147
SG&A to revenue (%): 49.70610399397136
Free cash flow (dilution-adjusted): 2189000
Buyback yield (%): 0
Retained earnings: -133210000
Receivables turnover: 1.9717682020802378
Capitalized R&D asset: 2654760
ROCI (R&D-adjusted, %): 6.100896320734141
Rosenberg metric: 0.44716031631919484
FCF margin (%): 32.991710625470986
Revenue growth (%): 10.325906218822748
Rule of 40 score: 43.31761684429374
Financial ratios for JAGSNPHARM.NS — annual report dated 2022-03-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 1.6000263747857049
Shares outstanding: 65929470
Market cap (USD): 105488890.87564288
Buyback yield (%): 0
Retained earnings: 9148226.295661349
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for JAGSNPHARM.NS — annual report dated 2023-03-31
Total revenue: 28832399.512789283
Gross profit: 17563946.406820953
Operating income: 4181485.9926918396
Net income: 3254689.40316687
Capital expenditures: 119123.02070645554
Operating cash flow: 5682704.019488429
Depreciation & amortization: 143118.1485992692
Net tangible assets: 19353227.771010965
Owner earnings: 3278684.5310596838
Return on net tangible assets (%): 16.941280130908176
Capex to operating income (%): 2.8488202738129913
Buffett classification: The Great
Stock price: 1.3658952496954935
P/E ratio: 27.668615567531155
Shares outstanding: 65929470
Book value: 19353227.771010965
P/B ratio: 4.653112697967147
Market cap (USD): 90052749.88794154
Debt to equity: 0.03776826735477374
Current ratio: 5.968553915345834
Quick ratio: 5.218635522831961
Effective tax rate (%): 23.233164789703515
Interest coverage ratio: 123.48920863309353
COGS to revenue (%): 39.08260601400846
SG&A to revenue (%): 9.913228621881258
Free cash flow (dilution-adjusted): 4576370.280146163
Buyback yield (%): 0
Retained earnings: 11514859.926918393
Inventory turnover: 4.474463145676146
Receivables turnover: 11.341222690686086
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 20.510828976848398
FCF margin (%): 15.872318494047668
Rule of 40 score: 15.872318494047668
Financial ratios for JAGSNPHARM.NS — annual report dated 2024-03-31
Total revenue: 25027221.489387218
Gross profit: 15417795.898788823
Operating income: 2591078.0669144983
Net income: 2693728.2647799496
Capital expenditures: 29739.776951672862
Operating cash flow: 4217052.404365032
Depreciation & amortization: 199424.3914138386
Net tangible assets: 22472958.38829596
Owner earnings: 2863412.879242115
Return on net tangible assets (%): 12.74159293924291
Capex to operating income (%): 1.1477761836441893
Buffett classification: The Great
Stock price: 1.2981046065259116
P/E ratio: 31.77133708392193
Shares outstanding: 65929470
Book value: 22472958.388295956
P/B ratio: 3.808281367947719
Market cap (USD): 85583348.7128119
Debt to equity: 0.0477102699010683
Current ratio: 10.287484316185695
Quick ratio: 9.5034504391468
Effective tax rate (%): 24.794937895476917
Interest coverage ratio: 27.80823680823681
COGS to revenue (%): 38.321146898448504
SG&A to revenue (%): 9.650602294180217
Free cash flow (dilution-adjusted): 2591197.9853699487
Buyback yield (%): 0
Retained earnings: 12494423.791821562
Inventory turnover: 5.3328665733146625
Receivables turnover: 19.057802940370742
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 10.91538267239202
FCF margin (%): 10.353518413814914
Revenue growth (%): -13.19757664191005
Rule of 40 score: -2.844058228095136
Financial ratios for JAGSNPHARM.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 12859292.881032012
Buffett classification: The Gruesome
Stock price: 1.959507883420927
Shares outstanding: 65929470
Book value: 23543119.923554707
P/B ratio: 5.487349027412064
Market cap (USD): 129189316.2147635
Debt to equity: 0.049791225907266756
Current ratio: 2.953459173033134
Quick ratio: 2.5959864654933926
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for JAGSNPHARM.NS — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 2.819442825504138
Shares outstanding: 65929470
Market cap (USD): 185884371.1807903
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for JAGSNPHARM.NS — annual report dated 2025-03-31
Total revenue: 31414075.28641571
Gross profit: 20140051.437923778
Operating income: 5019873.743277999
Net income: 6471954.641103577
Capital expenditures: 4134907.645545943
Operating cash flow: 6442950.666354922
Depreciation & amortization: 950549.4505494505
Net tangible assets: 18042202.47837269
Owner earnings: 3287596.4461070844
Return on net tangible assets (%): 18.22170242268342
Capex to operating income (%): 82.37074988355845
Buffett classification: The Gruesome
Stock price: 2.5091609289298633
P/E ratio: 25.560693694980124
Shares outstanding: 65929470
Book value: 28051204.1150339
P/B ratio: 5.897345779192183
Market cap (USD): 165427650.18905357
Debt to equity: 0.038503854969785374
Current ratio: 6.2227455219271155
Quick ratio: 5.635963557751699
Effective tax rate (%): 20.753231509182783
Interest coverage ratio: 44.822546972860124
COGS to revenue (%): 35.88844728263297
Free cash flow (dilution-adjusted): 5606850.596212298
Buyback yield (%): 0
Inventory turnover: 6.344605263157895
Receivables turnover: 20.39435336976321
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 17.01564456561366
FCF margin (%): 17.84821149466351
Revenue growth (%): 25.51962789691551
Rule of 40 score: 43.36783939157902
Financial ratios for JAGSNPHARM.NS — quarterly report dated 2025-03-31
Total revenue: 6845920.037409399
Gross profit: 4306757.072714519
Operating income: 749240.1215805471
Net income: 769593.1727846621
Capital expenditures: 0
Depreciation & amortization: 269464.57797521626
Net tangible assets: 18042202.47837269
Owner earnings: 1039057.7507598784
Return on net tangible assets (%): 5.7590405162862135
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 2.5091609289298633
P/E ratio: 53.73866870156781
Shares outstanding: 65929470
Book value: 28051204.1150339
P/B ratio: 5.897345779192183
Market cap (USD): 165427650.18905357
Debt to equity: 0.038503854969785374
Current ratio: 6.2227455219271155
Quick ratio: 5.635963557751699
Effective tax rate (%): 24.40284795590262
Interest coverage ratio: 24.745173745173748
COGS to revenue (%): 37.09016393442623
Buyback yield (%): 0
Inventory turnover: 1.4289473684210527
Receivables turnover: 4.444444444444445
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.539666185864414
Rule of 40 score: 0
Financial ratios for JAGSNPHARM.NS — quarterly report dated 2025-06-30
Total revenue: 8847648.022466652
Gross profit: 5696817.224432483
Operating income: 1387783.7584835012
Net income: 1263164.0533582964
Capital expenditures: 0
Depreciation & amortization: 275333.48935174354
Owner earnings: 1538497.54271004
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 2.59197285279663
P/E ratio: 84.06680062012076
Shares outstanding: 65929470
Market cap (USD): 170887396.43926984
Effective tax rate (%): 25.195759129651442
Interest coverage ratio: 46.69291338582677
COGS to revenue (%): 35.612072157858535
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): 29.23972196752006
Rule of 40 score: 29.23972196752006
Financial ratios for JAGSNPHARM.NS — quarterly report dated 2025-09-30
Total revenue: 8395152.198421646
Gross profit: 5325479.143179256
Operating income: 1583765.5016910934
Net income: 1417587.3731679819
Capital expenditures: 0
Depreciation & amortization: 268996.6178128523
Net tangible assets: 19285682.074408118
Owner earnings: 1686583.9909808342
Return on net tangible assets (%): 8.745264930084646
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 2.472040586245772
P/E ratio: 47.235955997618746
Shares outstanding: 65929470
Book value: 28505073.28072153
P/B ratio: 5.71759013087328
Market cap (USD): 162980325.66967306
Debt to equity: 0.03494700205663661
Current ratio: 6.065648671395936
Quick ratio: 5.589305037874233
Effective tax rate (%): 25.199286139202854
Interest coverage ratio: 53.01132075471698
COGS to revenue (%): 36.564829114349024
Buyback yield (%): 0
Inventory turnover: 1.7181800971792767
Receivables turnover: 3.299875919524949
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 5.285972305839856
Revenue growth (%): -5.114306343290248
Rule of 40 score: -5.114306343290248
Financial ratios for JAGSNPHARM.NS — quarterly report dated 2025-12-31
Total revenue: 8125765.84605102
Gross profit: 5179013.033307341
Operating income: 1546396.346218113
Net income: 1219895.2879581153
Capital expenditures: 0
Depreciation & amortization: 265790.3531246519
Owner earnings: 1485685.6410827672
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 2.145594296535591
P/E ratio: 30.289213877690663
Shares outstanding: 65929470
Market cap (USD): 141457894.80561435
Effective tax rate (%): 24.585083671923417
Interest coverage ratio: 54.01556420233464
COGS to revenue (%): 36.26430872575227
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): -3.2088322641878135
Rule of 40 score: -3.2088322641878135
Financial ratios for JIGI.L — annual report dated 2021-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 0.10851351351351352
Shares outstanding: 43643985
Market cap (USD): 4735962.156081081
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for JIGI.L — annual report dated 2022-09-30
Total revenue: 46070000
Net income: 49011111.11111111
Capital expenditures: 0
Operating cash flow: -3281111.111111111
Net tangible assets: 883610000
Owner earnings: 49011111.11111111
Return on net tangible assets (%): 5.546690407658482
Buffett classification: The Gruesome
Stock price: 0.08966666666666667
P/E ratio: 0.07984741758104738
Shares outstanding: 43643985
Book value: 883610000
P/B ratio: 0.004428889051730968
Market cap (USD): 3913410.6550000003
Debt to equity: 0
Effective tax rate (%): -9.42151220480254
COGS to revenue (%): 0
SG&A to revenue (%): 2.732556737332079
Free cash flow (dilution-adjusted): -3281111.111111111
Buyback yield (%): 362.684486362276
Receivables turnover: 7.63731810646528
Capitalized R&D asset: 0
FCF margin (%): -7.122012396594554
Rule of 40 score: -7.122012396594554
Financial ratios for JIGI.L — annual report dated 2023-09-30
Total revenue: 20058536.585365854
Net income: 3606097.56097561
Capital expenditures: 0
Operating cash flow: 1810975.6097560977
Net tangible assets: 945850000
Owner earnings: 3606097.56097561
Return on net tangible assets (%): 0.3812546979939324
Buffett classification: The Gruesome
Stock price: 0.10060975609756098
P/E ratio: 1.2176627536354414
Shares outstanding: 43643985
Book value: 945850000
P/B ratio: 0.004642396453957403
Market cap (USD): 4391010.68597561
Debt to equity: 0
Effective tax rate (%): 80.71605582365984
COGS to revenue (%): 0
SG&A to revenue (%): 6.68774319066148
Free cash flow (dilution-adjusted): 1810975.6097560977
Buyback yield (%): 623.1133915739251
Capitalized R&D asset: 0
FCF margin (%): 9.028453307392995
Revenue growth (%): -56.46074107799901
Rule of 40 score: -47.43228777060602
Financial ratios for JIGI.L — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 1147849333.3333333
Buffett classification: The Gruesome
Stock price: 0.1324
Shares outstanding: 43643985
Book value: 1147849333.3333333
P/B ratio: 0.005034165587934305
Market cap (USD): 5778463.613999999
Debt to equity: 0
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for JIGI.L — annual report dated 2024-09-30
Total revenue: 37449994.333333336
Net income: 169713333.33333334
Capital expenditures: 0
Operating cash flow: 3405333.3333333335
Net tangible assets: 1147849333.3333333
Owner earnings: 169713333.33333334
Return on net tangible assets (%): 14.785331872824194
Buffett classification: The Gruesome
Stock price: 0.1324
P/E ratio: 0.03404837734611305
Shares outstanding: 43643985
Book value: 1147849333.3333333
P/B ratio: 0.005034165587934305
Market cap (USD): 5778463.613999999
Debt to equity: 0
Effective tax rate (%): 22.426927671192807
COGS to revenue (%): 0
SG&A to revenue (%): 4.361371376442486
Free cash flow (dilution-adjusted): 3405333.3333333335
Buyback yield (%): 965.262344097774
Capitalized R&D asset: 0
FCF margin (%): 9.09301428198703
Revenue growth (%): 86.70352233300909
Rule of 40 score: 95.79653661499611
Financial ratios for JIGI.L — quarterly report dated 2025-03-31
Capital expenditures: 0
Net tangible assets: 989805194.8051947
Buffett classification: The Gruesome
Stock price: 0.12272727272727271
Shares outstanding: 43643985
Market cap (USD): 5356307.249999999
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for JIGI.L — annual report dated 2025-09-30
Total revenue: -126100000
Net income: -118606756.75675675
Capital expenditures: 0
Operating cash flow: 2350000
Net tangible assets: 678710810.8108108
Owner earnings: -118606756.75675675
Return on net tangible assets (%): -17.47530094814095
Buffett classification: The Gruesome
Stock price: 0.13175675675675677
Shares outstanding: 43643985
Book value: 678710810.8108108
P/B ratio: 0.008472518521800075
Market cap (USD): 5750389.9155405415
Debt to equity: 0.0006809412120753575
Free cash flow (dilution-adjusted): 2350000
Buyback yield (%): 6365.11478864669
Receivables turnover: -39.027185278126304
Capitalized R&D asset: 0
Revenue growth (%): -436.7156717771822
Rule of 40 score: -436.7156717771822
Financial ratios for JIGI.L — quarterly report dated 2025-09-30
Capital expenditures: 0
Net tangible assets: 678710810.8108108
Buffett classification: The Gruesome
Stock price: 0.13175675675675677
Shares outstanding: 43643985
Book value: 678710810.8108108
P/B ratio: 0.008472518521800075
Market cap (USD): 5750389.9155405415
Debt to equity: 0.0006809412120753575
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for JYOTICNC.NS — annual report dated 2024-03-31
Total revenue: 159954430.98692888
Gross profit: 69095814.84590478
Operating income: 32160930.567214295
Net income: 18090898.18923132
Capital expenditures: 13705480.27341408
Operating cash flow: -5786065.475476676
Depreciation & amortization: 3927329.415997122
Net tangible assets: 160825038.97349802
Owner earnings: 8312747.331814364
Return on net tangible assets (%): 5.168814125507037
Capex to operating income (%): 42.61531004138857
Buffett classification: The Good
Stock price: 9.854246641074857
P/E ratio: 123.87904991886242
Shares outstanding: 227423096
Book value: 163644321.8611344
P/B ratio: 13.694842903028357
Market cap (USD): 2241083279.8608446
Debt to equity: 0.22260979166514003
Current ratio: 2.4684838637382343
Quick ratio: 1.2554768041237114
Effective tax rate (%): 18.432008650986752
Interest coverage ratio: 3.3586725109580464
COGS to revenue (%): 56.80281288890888
SG&A to revenue (%): 5.5545559503995925
Free cash flow (dilution-adjusted): -19491545.748890754
Buyback yield (%): 0
Retained earnings: 1361074.4693608347
Inventory turnover: 0.8749177242231434
Receivables turnover: 5.354716981132075
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 18.313735130631922
FCF margin (%): -12.18568665377176
Revenue growth (%): 41.83512352575016
Rule of 40 score: 29.649436871978402
Financial ratios for JYOTICNC.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 175449593.8843765
Buffett classification: The Gruesome
Stock price: 13.678929765886288
Shares outstanding: 227423096
Book value: 178462374.5819398
P/B ratio: 17.431711107800282
Market cap (USD): 3110904557.3244147
Debt to equity: 0.16749894751778177
Current ratio: 2.7786098667250156
Quick ratio: 1.3604774932918313
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for JYOTICNC.NS — quarterly report dated 2025-03-31
Total revenue: 67299509.00163665
Gross profit: 36593406.59340659
Operating income: 19569791.91021744
Net income: 12740238.484919336
Capital expenditures: 0
Depreciation & amortization: 1197100.7715688567
Net tangible assets: 193783025.48515314
Owner earnings: 13937339.256488193
Return on net tangible assets (%): 7.19223947587505
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 12.353250087524799
P/E ratio: 55.1287635606797
Shares outstanding: 227423096
Book value: 197118307.2246902
P/B ratio: 14.25242748947098
Market cap (USD): 2809414380.5671606
Debt to equity: 0.29468315393055183
Current ratio: 2.1526072607260724
Quick ratio: 1.2381822797664381
Effective tax rate (%): 29.97943973271652
Interest coverage ratio: 14.774933804060018
COGS to revenue (%): 45.626042245692055
Buyback yield (%): 0
Retained earnings: 38163432.31236848
Inventory turnover: 0.29168887704335467
Receivables turnover: 1.1832120688946437
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 9.262845696705437
Rule of 40 score: 0
Financial ratios for JYOTICNC.NS — annual report dated 2025-03-31
Total revenue: 212497077.3906944
Gross profit: 110928220.71545476
Operating income: 53122515.78209025
Net income: 36942950.66635492
Capital expenditures: 36220481.64601356
Operating cash flow: -12325227.963525835
Depreciation & amortization: 4261164.367547346
Net tangible assets: 193783025.48515314
Owner earnings: 4983633.387888707
Return on net tangible assets (%): 2.5717595106236653
Capex to operating income (%): 68.18291850971589
Buffett classification: The Good
Stock price: 12.353250087524799
P/E ratio: 76.04737385326887
Shares outstanding: 227423096
Book value: 197118307.2246902
P/B ratio: 14.25242748947098
Market cap (USD): 2809414380.5671606
Debt to equity: 0.29468315393055183
Current ratio: 2.1526072607260724
Quick ratio: 1.2381822797664381
Effective tax rate (%): 24.352468042322972
Interest coverage ratio: 10.798716730038024
COGS to revenue (%): 47.79776640809815
SG&A to revenue (%): 5.5317159047147495
Free cash flow (dilution-adjusted): -48545709.60953939
Buyback yield (%): 0
Retained earnings: 38163432.31236848
Inventory turnover: 0.9648409737029141
Receivables turnover: 3.7359723763719326
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 25.14414404444395
FCF margin (%): -22.845354018814984
Revenue growth (%): 32.84850946583605
Rule of 40 score: 10.003155447021069
Financial ratios for JYOTICNC.NS — quarterly report dated 2025-06-30
Total revenue: 47995553.47531009
Gross profit: 26857009.127077
Operating income: 10292534.519073252
Net income: 8357126.140884625
Capital expenditures: 0
Depreciation & amortization: 1433419.1434589282
Owner earnings: 9790545.284343554
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 12.391762227942898
P/E ratio: 84.30448707084851
Shares outstanding: 227423096
Market cap (USD): 2818172930.7746315
Effective tax rate (%): 25.82052347320316
Interest coverage ratio: 7.22167487684729
COGS to revenue (%): 44.04271399663554
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): -28.683649870101007
Rule of 40 score: -28.683649870101007
Financial ratios for JYOTICNC.NS — quarterly report dated 2025-09-30
Total revenue: 57260428.41037204
Gross profit: 32069898.53438557
Operating income: 12864712.514092445
Net income: 9639233.37091319
Capital expenditures: 0
Depreciation & amortization: 1180383.3145434046
Net tangible assets: 202466741.82638106
Owner earnings: 10819616.685456596
Return on net tangible assets (%): 5.343898256008197
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 9.581736189402479
P/E ratio: 70.89620359032237
Shares outstanding: 227423096
Book value: 206400225.47914314
P/B ratio: 10.557682794146725
Market cap (USD): 2179108109.249154
Debt to equity: 0.3955985732779105
Current ratio: 2.338964489241315
Quick ratio: 1.343000263643554
Effective tax rate (%): 21.59559834938102
Interest coverage ratio: 8.041578576462296
COGS to revenue (%): 43.992911990549324
Buyback yield (%): 0
Inventory turnover: 0.22748930971288944
Receivables turnover: 1.434016601727935
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 5.4045989532763405
Revenue growth (%): 19.3036109893555
Rule of 40 score: 19.3036109893555
Financial ratios for JYOTICNC.NS — quarterly report dated 2025-12-31
Total revenue: 64152835.02283614
Gross profit: 36978946.1958338
Operating income: 15744680.85106383
Net income: 9859641.30555865
Capital expenditures: 0
Depreciation & amortization: 1473766.2916341764
Owner earnings: 11333407.597192826
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 11.020385429430767
P/E ratio: 61.73700363752495
Shares outstanding: 227423096
Market cap (USD): 2506290173.474435
Effective tax rate (%): 28.47676767676768
Interest coverage ratio: 5.978849407783418
COGS to revenue (%): 42.358048272269485
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): 12.03694559018637
Rule of 40 score: 12.03694559018637
Financial ratios for KEY.AX — annual report dated 2021-06-30
Operating income: -2360189.4736842103
Net income: -1679400.751879699
Capital expenditures: 3308.270676691729
Depreciation & amortization: 30821.804511278195
Net tangible assets: 2073169.1729323308
Owner earnings: -1651887.2180451127
Return on net tangible assets (%): -79.67932572085526
Buffett classification: The Gruesome
Stock price: 0.22556390977443608
Shares outstanding: 38919295
Book value: 2073169.172932331
P/B ratio: 4.234477562411258
Market cap (USD): 8778788.345864661
Debt to equity: 0.0741565617276227
Current ratio: 2.741478711762954
Quick ratio: 2.741478711762954
Interest coverage ratio: -292.3039389142378
Free cash flow (dilution-adjusted): -922192.4812030075
Buyback yield (%): 0
Retained earnings: -29917997.7443609
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -113.60057555706425
Rule of 40 score: 0
Financial ratios for KEY.AX — annual report dated 2022-06-30
Operating income: -471318.6206896552
Net income: -842951.724137931
Capital expenditures: 3448.2758620689656
Depreciation & amortization: 1403.448275862069
Net tangible assets: 1058644.8275862068
Owner earnings: -844996.551724138
Return on net tangible assets (%): -79.81870120225273
Buffett classification: The Gruesome
Stock price: 0.13793103448275862
Shares outstanding: 38919295
Book value: 1058644.827586207
P/B ratio: 5.070802294410224
Market cap (USD): 5368178.620689655
Debt to equity: 0.06667339832642252
Current ratio: 1.0638541296522623
Quick ratio: 1.0638541296522623
Interest coverage ratio: -77.52830402722633
Free cash flow (dilution-adjusted): -527973.1034482758
Buyback yield (%): 0
Retained earnings: -28262253.103448275
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -44.52093926197122
Rule of 40 score: 0
Financial ratios for KEY.AX — annual report dated 2023-06-30
Operating income: -458081.45695364237
Net income: 232034.43708609272
Capital expenditures: 74513.24503311259
Depreciation & amortization: 1323.841059602649
Net tangible assets: 1248613.9072847683
Owner earnings: 158845.03311258278
Return on net tangible assets (%): 12.721709424012959
Buffett classification: The Gruesome
Stock price: 0.06622516556291391
P/E ratio: 11.10799236240339
Shares outstanding: 38919295
Book value: 1248613.907284768
P/B ratio: 2.064238384603431
Market cap (USD): 2577436.7549668876
Debt to equity: 0
Current ratio: 1.9087213837653838
Quick ratio: 1.9087213837653838
Effective tax rate (%): 0
Interest coverage ratio: -19.472524069590676
Free cash flow (dilution-adjusted): -500677.4834437086
Buyback yield (%): 0
Retained earnings: -26907215.23178808
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -36.68719804265074
Rule of 40 score: 0
Financial ratios for KEY.AX — annual report dated 2024-06-30
Operating income: -657636.6666666666
Net income: -640928.6666666666
Capital expenditures: 11370
Depreciation & amortization: 92
Net tangible assets: 810885.3333333334
Owner earnings: -652206.6666666666
Return on net tangible assets (%): -80.43142968015205
Buffett classification: The Gruesome
Stock price: 0.06666666666666667
Shares outstanding: 38919295
Book value: 810885.3333333334
P/B ratio: 3.199736830854835
Market cap (USD): 2594619.6666666665
Debt to equity: 0
Current ratio: 0.6128952359625283
Quick ratio: 0.6128952359625283
Free cash flow (dilution-adjusted): -480340
Buyback yield (%): 0.06901461087617337
Retained earnings: -27727525.333333332
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -81.10106813293781
Rule of 40 score: 0
Financial ratios for LAB — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 3.92
Shares outstanding: 391462923
Market cap (USD): 1534534658.16
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for LAB — annual report dated 2022-12-31
Total revenue: 97948000
Gross profit: 37051000
Operating income: -102616000
Net income: -190098000
Capital expenditures: 3825000
Operating cash flow: -89370000
Depreciation & amortization: 15027000
Net tangible assets: -200318000
Owner earnings: -178896000
Buffett classification: The Gruesome
Stock price: 1.17
Shares outstanding: 391462923
Book value: -81467000
Market cap (USD): 458011619.90999997
Debt to equity: -1.2600807689002909
Current ratio: 4.806643187625164
Quick ratio: 4.31236332665792
Interest coverage ratio: -23.6933733548834
COGS to revenue (%): 62.172785559684726
R&D to revenue (%): 38.16514885449423
SG&A to revenue (%): 104.42785968064688
Free cash flow (dilution-adjusted): -108075000
Buyback yield (%): 0.12292264552384727
Retained earnings: -926096000
Inventory turnover: 2.8359800679923626
Receivables turnover: 5.668287037037037
Capitalized R&D asset: 37382000
ROCI (R&D-adjusted, %): -20.219874786054532
FCF margin (%): -110.33915955404909
Rule of 40 score: -110.33915955404909
Financial ratios for LAB — annual report dated 2023-12-31
Total revenue: 106340000
Gross profit: 50450000
Operating income: -63039000
Net income: -74656000
Capital expenditures: 2831000
Operating cash flow: -43287000
Depreciation & amortization: 15180000
Net tangible assets: -255768000
Owner earnings: -62307000
Buffett classification: The Gruesome
Stock price: 2.21
Shares outstanding: 391462923
Book value: -148051000
Market cap (USD): 865133059.83
Debt to equity: -0.6633524933975454
Current ratio: 1.4471722447336888
Quick ratio: 1.259359536070687
Interest coverage ratio: -13.803153054521568
COGS to revenue (%): 52.55783336467933
R&D to revenue (%): 24.400977995110022
SG&A to revenue (%): 82.32179800639459
Free cash flow (dilution-adjusted): -59241000
Buyback yield (%): 0.625799689248248
Retained earnings: -1000752000
Inventory turnover: 2.721959772074222
Receivables turnover: 5.408952187182096
Capitalized R&D asset: 50993940
ROCI (R&D-adjusted, %): -21.984714162453063
Rosenberg metric: 0.35843454068803166
FCF margin (%): -55.70904645476773
Revenue growth (%): 8.567811491811982
Rule of 40 score: -47.14123496295575
Financial ratios for LAB — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 1.93
Shares outstanding: 391462923
Market cap (USD): 755523441.39
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for LAB — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 1.75
Shares outstanding: 391462923
Market cap (USD): 685060115.25
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for LAB — annual report dated 2024-12-31
Total revenue: 91008000
Gross profit: 44883000
Operating income: -87006000
Net income: -138885000
Capital expenditures: 8355000
Operating cash flow: -143454000
Depreciation & amortization: 16861000
Net tangible assets: 471722000
Owner earnings: -130379000
Return on net tangible assets (%): -27.638948363654865
Buffett classification: The Gruesome
Stock price: 1.75
Shares outstanding: 391462923
Book value: 471722000
P/B ratio: 1.4522539021923928
Market cap (USD): 685060115.25
Debt to equity: 0.0650701048498904
Current ratio: 5.7042719477957355
Quick ratio: 5.389468093178541
Interest coverage ratio: -26.238238841978287
COGS to revenue (%): 50.68235759493671
R&D to revenue (%): 31.679632559774966
SG&A to revenue (%): 113.24059423347398
Free cash flow (dilution-adjusted): -183541000
Buyback yield (%): 5.910430208774295
Retained earnings: -1185651000
Inventory turnover: 2.223534516004628
Receivables turnover: 6.173800963299641
Capitalized R&D asset: 58552220
ROCI (R&D-adjusted, %): -14.693389609931238
Rosenberg metric: -0.21454447356250964
FCF margin (%): -201.67567686357245
Revenue growth (%): -14.417904833552756
Rule of 40 score: -216.09358169712522
Financial ratios for LAB — quarterly report dated 2025-03-31
Total revenue: 20222000
Gross profit: 11049000
Operating income: -24215000
Net income: -26033000
Capital expenditures: 5054000
Operating cash flow: -30283000
Depreciation & amortization: 4171000
Net tangible assets: 314819000
Owner earnings: -26916000
Return on net tangible assets (%): -8.549674574914475
Buffett classification: The Gruesome
Stock price: 1.08
Shares outstanding: 391462923
Book value: 454595000
P/B ratio: 0.9300145334638524
Market cap (USD): 422779956.84000003
Debt to equity: 0.06935843993004763
Current ratio: 6.117415890177111
Quick ratio: 5.368340564762786
Interest coverage ratio: -12107.5
COGS to revenue (%): 45.3614874888735
R&D to revenue (%): 26.90139452081891
SG&A to revenue (%): 147.48293937296015
Free cash flow (dilution-adjusted): -44346000
Buyback yield (%): 0
Retained earnings: -1211684000
Inventory turnover: 0.2177566765578635
Receivables turnover: 0.5699549041713642
Capitalized R&D asset: 5440000
ROCI (R&D-adjusted, %): -3.8933990921600623
FCF margin (%): -219.29581643754327
Rule of 40 score: -219.29581643754327
Financial ratios for LAB — quarterly report dated 2025-06-30
Total revenue: 21762000
Gross profit: 10628000
Operating income: -23699000
Net income: -33459000
Capital expenditures: 1887000
Operating cash flow: -20668000
Depreciation & amortization: 3994000
Net tangible assets: 424535000
Owner earnings: -31352000
Return on net tangible assets (%): -7.385021258553476
Buffett classification: The Gruesome
Stock price: 1.2
Shares outstanding: 391462923
Book value: 424535000
P/B ratio: 1.106517737289034
Market cap (USD): 469755507.59999996
Debt to equity: 0.06740551426855265
Current ratio: 5.1623786011589
Quick ratio: 4.915806333142903
Interest coverage ratio: -2633.222222222222
COGS to revenue (%): 51.162576969028585
R&D to revenue (%): 28.591122139509235
SG&A to revenue (%): 129.14713721165333
Free cash flow (dilution-adjusted): -28942000
Buyback yield (%): 0
Retained earnings: -1245143000
Inventory turnover: 0.46065370293752583
Receivables turnover: 1.48932384341637
Capitalized R&D asset: 9866800
ROCI (R&D-adjusted, %): -4.557162515925147
Rosenberg metric: -0.07738970588235294
FCF margin (%): -132.9932910578072
Revenue growth (%): 7.615468301849471
Rule of 40 score: -125.37782275595772
Financial ratios for LAB — quarterly report dated 2025-09-30
Total revenue: 19552000
Gross profit: 9484000
Operating income: -23467000
Net income: -34687000
Capital expenditures: 886000
Operating cash flow: -22202000
Depreciation & amortization: 1521000
Net tangible assets: 399659000
Owner earnings: -34052000
Return on net tangible assets (%): -8.520263524654768
Buffett classification: The Gruesome
Stock price: 1.3
Shares outstanding: 391462923
Book value: 399659000
P/B ratio: 1.2733400221188564
Market cap (USD): 508901799.90000004
Debt to equity: 0.06853092261152632
Current ratio: 4.375853285787061
Quick ratio: 4.140425137776131
Interest coverage ratio: -2346.7
COGS to revenue (%): 51.49345335515548
R&D to revenue (%): 32.50818330605565
SG&A to revenue (%): 136.02189034369886
Free cash flow (dilution-adjusted): -31562000
Buyback yield (%): 0
Retained earnings: -1279830000
Inventory turnover: 0.39609725391454875
Receivables turnover: 1.4444444444444444
Capitalized R&D asset: 12319940
ROCI (R&D-adjusted, %): -5.206637775086131
Rosenberg metric: -0.1838637094181935
FCF margin (%): -161.4259410801964
Revenue growth (%): -10.15531660692951
Rule of 40 score: -171.5812576871259
Financial ratios for LAB — annual report dated 2025-12-31
Total revenue: 85331000
Gross profit: 42543000
Operating income: -93305000
Net income: -74896000
Capital expenditures: 8303000
Operating cash flow: -74343000
Depreciation & amortization: 10977000
Net tangible assets: 424291000
Owner earnings: -72222000
Return on net tangible assets (%): -17.021808145824448
Buffett classification: The Gruesome
Stock price: 1.28
Shares outstanding: 391462923
Book value: 424291000
P/B ratio: 1.180964341548607
Market cap (USD): 501072541.44
Debt to equity: 0.07265532382256518
Current ratio: 4.194186948332534
Quick ratio: 4.009703807659637
Interest coverage ratio: -3588.653846153846
COGS to revenue (%): 50.143558612930825
R&D to revenue (%): 30.454348361087995
SG&A to revenue (%): 128.74687979749447
Free cash flow (dilution-adjusted): -112259000
Buyback yield (%): 0
Retained earnings: -1260547000
Inventory turnover: 2.1414343626445125
Receivables turnover: 6.35328717146899
Capitalized R&D asset: 53866610
ROCI (R&D-adjusted, %): -18.359182721032315
Rosenberg metric: -0.08116263743886788
FCF margin (%): -131.55711288980558
Revenue growth (%): -6.237913150492265
Rule of 40 score: -137.79502604029784
Financial ratios for LAB — quarterly report dated 2025-12-31
Total revenue: 23795000
Gross profit: 11382000
Operating income: -21924000
Net income: 19283000
Capital expenditures: 476000
Operating cash flow: -1190000
Depreciation & amortization: 1291000
Net tangible assets: 424291000
Owner earnings: 20098000
Return on net tangible assets (%): 4.7368433457226296
Buffett classification: The Gruesome
Stock price: 1.28
P/E ratio: 6.4962990903905
Shares outstanding: 391462923
Book value: 424291000
P/B ratio: 1.180964341548607
Market cap (USD): 501072541.44
Debt to equity: 0.07265532382256518
Current ratio: 4.194186948332534
Quick ratio: 4.009703807659637
Interest coverage ratio: -4384.8
COGS to revenue (%): 52.16642151712545
R&D to revenue (%): 33.49022903971422
SG&A to revenue (%): 106.48035301533936
Free cash flow (dilution-adjusted): -7409000
Buyback yield (%): 0
Retained earnings: -1260547000
Inventory turnover: 0.6212401781692608
Receivables turnover: 1.77164768073859
Capitalized R&D asset: 14280780
ROCI (R&D-adjusted, %): -4.391560890857806
Rosenberg metric: 0.2986154814348647
FCF margin (%): -31.136793444000844
Revenue growth (%): 21.70110474631751
Rule of 40 score: -9.435688697683332
Financial ratios for LMP.L — annual report dated 2022-03-31
Total revenue: 175263157.89473683
Gross profit: 173289473.68421054
Operating income: 152236842.10526314
Net income: 971315789.4736842
Capital expenditures: 67105263.15789474
Operating cash flow: 157236842.10526314
Depreciation & amortization: 789473.6842105263
Net tangible assets: 3368026315.7894735
Owner earnings: 905000000
Return on net tangible assets (%): 26.870336367543075
Capex to operating income (%): 44.079515989628355
Buffett classification: The Good
Stock price: 0.028421052631578948
P/E ratio: 0.06849923232728258
Shares outstanding: 2341024690
Book value: 3381315789.4736843
P/B ratio: 0.019677069540042027
Market cap (USD): 66534385.92631579
Debt to equity: 0.39925286014475836
Current ratio: 1.4595959595959593
Quick ratio: 1.441077441077441
Effective tax rate (%): 0.013544629554381689
Interest coverage ratio: 5.307339449541284
COGS to revenue (%): 1.1261261261261262
SG&A to revenue (%): 2.1771771771771773
Free cash flow (dilution-adjusted): 85526315.78947368
Buyback yield (%): 0
Retained earnings: 2071447368.4210527
Inventory turnover: 1.3636363636363638
Receivables turnover: 23.368421052631575
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.2176428054953
FCF margin (%): 48.798798798798806
Rule of 40 score: 48.798798798798806
Financial ratios for LMP.L — annual report dated 2023-03-31
Total revenue: 181111111.1111111
Gross profit: 179259259.25925925
Operating income: 159012345.67901233
Net income: -625061728.3950617
Capital expenditures: 20864197.530864198
Operating cash flow: 164197530.86419752
Depreciation & amortization: 740740.7407407407
Net tangible assets: 2428765432.0987654
Owner earnings: -645185185.1851852
Return on net tangible assets (%): -26.56432674223555
Capex to operating income (%): 13.121118012422361
Buffett classification: The Great
Stock price: 0.017777777777777778
Shares outstanding: 2341024690
Book value: 2463209876.5432096
P/B ratio: 0.016895927995188454
Market cap (USD): 41618216.71111111
Debt to equity: 0.5096732157177226
Current ratio: 0.45301757066462944
Quick ratio: 0.4446142093200916
Interest coverage ratio: 4.380952380952381
COGS to revenue (%): 1.0224948875255622
SG&A to revenue (%): 2.249488752556237
Free cash flow (dilution-adjusted): 138888888.88888887
Buyback yield (%): 0
Retained earnings: 1201975308.6419752
Inventory turnover: 1.3636363636363638
Receivables turnover: 58.68
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 4.3703980183909605
FCF margin (%): 76.68711656441717
Revenue growth (%): 3.336670003336675
Rule of 40 score: 80.02378656775385
Financial ratios for LMP.L — annual report dated 2024-03-31
Total revenue: 225443037.97468352
Gross profit: 223291139.24050632
Operating income: 198354430.37974682
Net income: 151772151.89873418
Capital expenditures: 7341772.151898734
Operating cash flow: 155822784.81012657
Depreciation & amortization: 886075.9493670886
Net tangible assets: 4989240506.329114
Owner earnings: 145316455.69620252
Return on net tangible assets (%): 2.9125967271343396
Capex to operating income (%): 3.7013401403956605
Buffett classification: The Great
Stock price: 0.022278481012658228
P/E ratio: 0.34363665174311925
Shares outstanding: 2341024690
Book value: 5024683544.303798
P/B ratio: 0.010379653493890917
Market cap (USD): 52154474.10632911
Debt to equity: 0.534626527270437
Current ratio: 0.683732057416268
Quick ratio: 0.6784688995215311
Effective tax rate (%): 0.08333333333333333
Interest coverage ratio: 3.821951219512195
COGS to revenue (%): 0.9545199326221224
SG&A to revenue (%): 2.3020774845592364
Free cash flow (dilution-adjusted): 144050632.9113924
Buyback yield (%): 0
Retained earnings: 1254556962.0253165
Inventory turnover: 1.5454545454545454
Receivables turnover: 16.339449541284402
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.499362000765599
FCF margin (%): 63.89668725435149
Revenue growth (%): 24.477751028966367
Rule of 40 score: 88.37443828331786
Financial ratios for LMP.L — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 5367466666.666667
Buffett classification: The Gruesome
Stock price: 0.0244
Shares outstanding: 2341024690
Book value: 5405200000
P/B ratio: 0.01056778702656701
Market cap (USD): 57121002.436000004
Debt to equity: 0.5393818298428673
Current ratio: 0.6502976190476191
Quick ratio: 0.6448412698412699
Buyback yield (%): 0
Retained earnings: 1420666666.6666667
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for LMP.L — annual report dated 2025-03-31
Total revenue: 515194805.1948052
Gross profit: 508831168.83116883
Operating income: 473636363.6363636
Net income: 455324675.3246753
Capital expenditures: 42727272.72727273
Operating cash flow: 411558441.5584415
Depreciation & amortization: 779220.7792207792
Net tangible assets: 5317142857.142857
Owner earnings: 413376623.37662333
Return on net tangible assets (%): 7.774412583654926
Capex to operating income (%): 9.021113243761997
Buffett classification: The Great
Stock price: 0.021948051948051946
P/E ratio: 0.11284460142897888
Shares outstanding: 2341024690
Book value: 5355714285.714286
P/B ratio: 0.009593665525594703
Market cap (USD): 51380931.507792205
Debt to equity: 0.5092509517689565
Current ratio: 0.21284256851370276
Quick ratio: 0.21064212842568517
Effective tax rate (%): 0.6235827664399093
Interest coverage ratio: 3.174064403829417
COGS to revenue (%): 1.2351903201411645
SG&A to revenue (%): 1.4620620115956642
Free cash flow (dilution-adjusted): 361948051.9480519
Buyback yield (%): 0
Retained earnings: 1475584415.5844154
Inventory turnover: 4.454545454545454
Receivables turnover: 110.19444444444444
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 5.9711511698347985
FCF margin (%): 70.25460045374338
Revenue growth (%): 128.52548910943074
Rule of 40 score: 198.7800895631741
Financial ratios for LMP.L — quarterly report dated 2025-03-31
Capital expenditures: 0
Net tangible assets: 5317142857.142857
Buffett classification: The Gruesome
Stock price: 0.021948051948051946
Shares outstanding: 2341024690
Book value: 5355714285.714286
P/B ratio: 0.009593665525594703
Market cap (USD): 51380931.507792205
Debt to equity: 0.5092509517689565
Current ratio: 0.21284256851370276
Quick ratio: 0.21064212842568517
Buyback yield (%): 0
Retained earnings: 1475584415.5844154
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for LMP.L — quarterly report dated 2025-09-30
Capital expenditures: 0
Net tangible assets: 6333108108.1081085
Buffett classification: The Gruesome
Stock price: 0.02337837837837838
Shares outstanding: 2341024690
Book value: 6372972972.972973
P/B ratio: 0.008587728400551315
Market cap (USD): 54729360.995945945
Debt to equity: 0.6026293469041561
Current ratio: 0.3776252573781744
Quick ratio: 0.37611530542210025
Buyback yield (%): 0
Retained earnings: 1534189189.1891892
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for LU2.DE — annual report dated 2021-06-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 83.45238095238095
Shares outstanding: 77800000
Market cap (USD): 6492595238.095238
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for LU2.DE — annual report dated 2022-06-30
Total revenue: 1712600000
Gross profit: 788600000
Operating income: 302200000
Net income: 198900000
Capital expenditures: 84800000
Operating cash flow: 459300000
Depreciation & amortization: 167100000
Net tangible assets: 1350400000
Owner earnings: 281200000
Return on net tangible assets (%): 20.82345971563981
Capex to operating income (%): 28.06088682991397
Buffett classification: The Good
Stock price: 80.3125
P/E ratio: 31.414341377576672
Shares outstanding: 77800000
Book value: 1875000000
P/B ratio: 3.3324333333333334
Market cap (USD): 6248312500
Debt to equity: 1.0325333333333333
Current ratio: 4.381297976273552
Quick ratio: 4.032240055826937
Effective tax rate (%): 15.397703105061675
Interest coverage ratio: 3.7680798004987532
COGS to revenue (%): 53.95305383627233
R&D to revenue (%): 12.886838724746
SG&A to revenue (%): 15.51442251547355
Free cash flow (dilution-adjusted): 265000000
Buyback yield (%): 8.704750282576295
Retained earnings: -129100000
Inventory turnover: 3.6945221911235504
Receivables turnover: 6.536641221374046
Capitalized R&D asset: 220700000
ROCI (R&D-adjusted, %): 12.255436759037021
FCF margin (%): 15.473548989840008
Rule of 40 score: 15.473548989840008
Financial ratios for LU2.DE — annual report dated 2023-06-30
Total revenue: 1767000000
Gross profit: 569000000
Operating income: -87600000
Net income: -131600000
Capital expenditures: 128200000
Operating cash flow: 179800000
Depreciation & amortization: 255600000
Net tangible assets: 201500000
Owner earnings: -4200000
Return on net tangible assets (%): -2.0843672456575684
Buffett classification: The Gruesome
Stock price: 57.55434782608696
Shares outstanding: 77800000
Book value: 1355800000
P/B ratio: 3.302646600434847
Market cap (USD): 4477728260.869566
Debt to equity: 2.119560407139696
Current ratio: 4.382928368570527
Quick ratio: 3.738245503313348
Interest coverage ratio: -2.4676056338028167
COGS to revenue (%): 67.79852857951329
R&D to revenue (%): 17.419354838709676
SG&A to revenue (%): 19.739671760045276
Free cash flow (dilution-adjusted): -97100000
Buyback yield (%): 3.92163145616833
Retained earnings: -340600000
Inventory turnover: 2.9319627998042095
Receivables turnover: 7.180008126777732
Capitalized R&D asset: 455669000
ROCI (R&D-adjusted, %): 0.9886313383261838
Rosenberg metric: -0.9950158586316267
FCF margin (%): -5.495189586870402
Revenue growth (%): 3.1764568492350813
Rule of 40 score: -2.3187327376353206
Financial ratios for LU2.DE — annual report dated 2024-06-30
Total revenue: 1359200000
Gross profit: 251500000
Operating income: -361400000
Net income: -546500000
Capital expenditures: 132200000
Operating cash flow: 24700000
Depreciation & amortization: 290300000
Net tangible assets: -716000000
Owner earnings: -388400000
Buffett classification: The Gruesome
Stock price: 38.255319148936174
Shares outstanding: 77800000
Book value: 957300000
P/B ratio: 3.109018938459453
Market cap (USD): 2976263829.7872343
Debt to equity: 2.673769978063303
Current ratio: 5.904567396955069
Quick ratio: 4.425176383215745
Interest coverage ratio: -10.692307692307692
COGS to revenue (%): 81.49646851088875
R&D to revenue (%): 22.233666862860506
SG&A to revenue (%): 22.859034726309595
Free cash flow (dilution-adjusted): -241100000
Buyback yield (%): 0
Retained earnings: -887100000
Inventory turnover: 2.780371485943775
Receivables turnover: 6.980996404725218
Capitalized R&D asset: 581257000
ROCI (R&D-adjusted, %): -7.919682496370636
Rosenberg metric: -1.0315139701104614
FCF margin (%): -17.738375515008826
Revenue growth (%): -23.07866440294284
Rule of 40 score: -40.81703991795167
Financial ratios for LU2.DE — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 38.255319148936174
Shares outstanding: 77800000
Market cap (USD): 2976263829.7872343
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for LU2.DE — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 38.255319148936174
Shares outstanding: 77800000
Market cap (USD): 2976263829.7872343
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for LU2.DE — quarterly report dated 2025-03-31
Total revenue: 425200000
Gross profit: 122500000
Operating income: -65400000
Net income: -44100000
Capital expenditures: 62700000
Operating cash flow: -1600000
Depreciation & amortization: 60100000
Net tangible assets: -681200000
Owner earnings: -46700000
Buffett classification: The Gruesome
Stock price: 38.255319148936174
Shares outstanding: 77800000
Book value: 879500000
P/B ratio: 3.3840407388143654
Market cap (USD): 2976263829.7872343
Debt to equity: 2.967367822626492
Current ratio: 4.723229461756374
Quick ratio: 3.5252124645892353
Interest coverage ratio: -11.473684210526315
COGS to revenue (%): 71.19002822201317
R&D to revenue (%): 17.850423330197554
SG&A to revenue (%): 26.340545625587957
Free cash flow (dilution-adjusted): -127200000
Buyback yield (%): 0
Retained earnings: -1074500000
Inventory turnover: 0.7157720501300544
Receivables turnover: 1.6628861947594837
Capitalized R&D asset: 75900000
ROCI (R&D-adjusted, %): -0.4002271559533789
FCF margin (%): -29.915333960489182
Rule of 40 score: -29.915333960489182